Want to see JP:4578 full AI Analyst Report?
4578 Stock Chart & Stats
¥8150.00
-¥102.00(-1.20%)
At close: 4:00 PM EST
¥8150.00
-¥102.00(-1.20%)
Day’s Range― - ―
52-Week Range¥6,511.00 - ¥11,910.00
Previous CloseN/A
Volume1.16M
Average Volume (3M)1.11M
Market Cap
¥5.96T
Enterprise Value¥5.30T
Total Cash (Recent Filing)¥538.30B
Total Debt (Recent Filing)¥194.63B
Price to Earnings (P/E)16.3
Beta0.62
Next Earnings
Jul 31, 2026EPS Estimate
152.13Next Dividend Ex-DateN/A
Dividend Yield1.42%
Share Statistics
EPS (TTM)713.14
Shares Outstanding542,988,900
10 Day Avg. Volume977,130
30 Day Avg. Volume1,112,043
Financial Highlights & Ratios
PEG Ratio1.60
Price to Book (P/B)1.55
Price to Sales (P/S)1.91
P/FCF Ratio14.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥12,953.33Price Target Upside58.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)592.13
Revenue Forecast (FY)¥2.59T
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageVery low debt-to-equity and steady growth in equity and assets give durable financial flexibility. This conservatism supports sustained R&D investment, withstands healthcare market swings, and preserves capacity for acquisitions or lifecycle spending without forcing distressed capital raises.
Sustained Revenue Expansion And Stronger MarginsMeaningful revenue expansion and improved gross and operating margins indicate structural gains in product adoption and pricing mix. Higher and more stable margins enhance reinvestment capacity for global commercialization and R&D, supporting medium-term earnings resilience.
Positive Free Cash Flow And Healthy Cash GenerationConsistent positive free cash flow in absolute terms provides a durable source of internally generated funds for dividends, R&D, and capex. Even with imperfect conversion, sustained FCF supports steady capital allocation without heavy reliance on external financing.
Bears Say
OCF Materially Below Net IncomeOperating cash generation lagging reported earnings suggests working-capital timing or non-cash profit drivers. Over months this can constrain discretionary spending and raises questions about earnings quality, requiring closer monitoring of cash conversion to validate profitability.
Free Cash Flow VolatilitySignificant swings in free cash flow reduce predictability for dividends, buybacks, and M&A. Structural volatility complicates multi-quarter planning and may force conservative capital allocation or reserve buffers, limiting the firm's ability to scale investments consistently.
Uneven Year-to-year Performance / Possible One-off Step-upInconsistent annual performance and signs of a one-off revenue step increase heighten forecasting risk. If recent gains reflect episodic events rather than sustainable demand, management faces greater uncertainty in hitting multi-quarter targets and justifying long-term capacity or R&D spend.
4578 FAQ
What was Otsuka Holdings Co Ltd’s price range in the past 12 months?
Otsuka Holdings Co Ltd lowest stock price was ¥6511.00 and its highest was ¥11910.00 in the past 12 months.
What is Otsuka Holdings Co Ltd’s market cap?
Otsuka Holdings Co Ltd’s market cap is ¥5.96T.
When is Otsuka Holdings Co Ltd’s upcoming earnings report date?
Otsuka Holdings Co Ltd’s upcoming earnings report date is Jul 31, 2026 which is in 24 days.
How were Otsuka Holdings Co Ltd’s earnings last quarter?
Otsuka Holdings Co Ltd released its earnings results on Apr 28, 2026. The company reported ¥186.31 earnings per share for the quarter, beating the consensus estimate of ¥136.268 by ¥50.042.
Is Otsuka Holdings Co Ltd overvalued?
According to Wall Street analysts Otsuka Holdings Co Ltd’s price is currently Undervalued.
Does Otsuka Holdings Co Ltd pay dividends?
Otsuka Holdings Co Ltd pays a Semiannually dividend of ¥70 which represents an annual dividend yield of 1.42%. See more information on Otsuka Holdings Co Ltd dividends here
What is Otsuka Holdings Co Ltd’s EPS estimate?
Otsuka Holdings Co Ltd’s EPS estimate is 152.13.
How many shares outstanding does Otsuka Holdings Co Ltd have?
Otsuka Holdings Co Ltd has 542,988,900 shares outstanding.
What happened to Otsuka Holdings Co Ltd’s price movement after its last earnings report?
Otsuka Holdings Co Ltd reported an EPS of ¥186.31 in its last earnings report, beating expectations of ¥136.268. Following the earnings report the stock price went up 5.026%.
Which hedge fund is a major shareholder of Otsuka Holdings Co Ltd?
Currently, no hedge funds are holding shares in JP:4578
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Otsuka Holdings Co Ltd
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment and tools, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement equipment, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, quasi-drugs, household products, and packaging materials and electronic parts. In addition, it offers IT solutions; adhesive tapes; flaky titanate and compounds; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; rental of space and office businesses; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. The company was founded in 1921 and is headquartered in Chiyoda, Japan.
4578 Company Deck
4578 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong growth in revenue and business profit, driven by pharmaceutical and nutraceutical segments. Forecasts have been revised upward, and there is an acquisition to further enhance drug discovery capabilities. However, there were some negatives, such as impairment losses and a decrease in certain revenues. Overall, the positive aspects significantly outweigh the negatives, indicating a strong performance and optimistic outlook.View all JP:4578 earnings summaries4578 Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
¥12,953.33
▲(58.94% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Astellas Pharma
―
Chugai Pharmaceutical Co
―
Daiichi Sankyo Company
―
Eisai Co
―
Takeda Pharmaceutical Co
―
Options Prices
Currently, No data available
---











